Comparative Pharmacology
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus HYDERGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus HYDERGINE.
DIHYDROERGOTAMINE MESYLATE vs HYDERGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.
1-2 mg orally three times daily.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 7-13 hours) after IM administration; clinical effect duration corresponds to this elimination phase.
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
Primarily hepatic metabolism; <10% excreted unchanged in urine; biliary/fecal excretion accounts for ~90% of metabolites.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid